Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits in the top decile of US sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 523 sponsored US clinical trials, 69 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors 523 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 301 completed. 5 of these trials are in Phase 3-4 (later-stage) and 395 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 17 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ranks in the top decile of sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
301 of 415 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
523 total, page 6 of 11
A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
NCT02048384
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
NCT01900496
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
NCT02096588
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
NCT01861340
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
NCT02151760
A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers
NCT02188563
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
NCT01966289
A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
NCT02111187
Red Cell Transfusion Goals in Patients With Acute Leukemias
NCT02086773
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
NCT02115828
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
NCT01845805
Stereotactic Body Radiation With Nelfinavir for Oligometastases
NCT01728779
A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
NCT02046694
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
NCT01588951
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
NCT01928576
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
NCT01896869
Stereotactic Radiation Therapy for Pediatric Sarcomas
NCT01763970
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
NCT01896856
Tumor Motion Management in Radiotherapy Using 4D-MRI
NCT01934855
Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer
NCT01983709
IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
NCT01939847
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
NCT01876511
Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
NCT01858558
SRS (Stereotactic Radiosurgery) Plus Ipilimumab
NCT01950195
Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
NCT01886105
Robot-Assisted MRI-Guided Prostate Biopsy
NCT02080052
POWER-remote Weight Loss Program in Early Stage Breast Cancer
NCT01871116
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
NCT01700673
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
NCT01836068
Radiation and Androgen Ablation for Prostate Cancer
NCT01517451
Radiotherapy for Solid Tumor Spine Metastases
NCT01752036
Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
NCT01729260
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer
NCT01797159
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
NCT01688401
Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
NCT01815515
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
NCT01752023
Group Intervention to Increase Physical Activity in Childhood Cancer Survivors
NCT01835509
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
NCT01696877
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
NCT01781728
DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
NCT01763931
Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
NCT01750398
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
NCT01715233
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
NCT01732640
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
NCT01595321
Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
NCT01496157
Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma
NCT01639131
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
NCT01665768
A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
NCT01697800
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
NCT01502605
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 185 |
| Phase 2 | 210 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline
69 recruiting of 523 indexed (13% open); 301 completed (58%).
Phase mix: 5 late (III/IV) vs 395 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: open-pipeline peers nationwide
Peers matched on 523 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 523 trials (± recruiting share)
- AbbVie · 526 trials · 21% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 13% open enrollment (± trial volume)
- MetroHealth Medical Center · 13% recruiting · 76 trials
- Texas Tech University Health Sciences Center · 13% recruiting · 76 trials
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins page
523 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins or any single study.
- 69 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline card: 523 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.